Altiratinib is a potent small-molecule tyrosine kinase inhibitor primarily investigated for its role in oncology, particularly in the treatment of advanced solid tumors. It is designed to target multiple receptor tyrosine kinases, including MET, TRK (tropomyosin receptor kinase), and TIE2, which are implicated in tumor growth, metastasis, and angiogenesis. By inhibiting these kinases, altiratinib disrupts signaling pathways that drive cancer progression. It has shown promise in preclinical and clinical studies for cancers with specific genetic alterations, such as MET amplifications or exon 14 skipping mutations, and NTRK gene fusions, which are found in various tumor types including non-small cell lung cancer, glioblastoma, and other central nervous system tumors. Due to its ability to cross the blood-brain barrier, altiratinib is of particular interest in treating brain metastases and primary brain tumors where effective drug penetration is a major challenge. The compound has been evaluated in phase 1 clinical trials to assess safety, pharmacokinetics, and preliminary efficacy in patients with advanced cancers. Its multi-target profile makes it a candidate for use in tumors resistant to other kinase inhibitors, offering a potential therapeutic option in precision oncology.